Inogen, Inc (NASDAQ:INGN) EVP Matt Scribner sold 2,500 shares of the firm’s stock in a transaction on Monday, September 11th. The stock was sold at an average price of $103.23, for a total transaction of $258,075.00. Following the sale, the executive vice president now owns 6,964 shares in the company, valued at $718,893.72. The sale was disclosed in a document filed with the Securities & Exchange Commission, which can be accessed through the SEC website.
Matt Scribner also recently made the following trade(s):
- On Friday, August 18th, Matt Scribner sold 2,500 shares of Inogen stock. The stock was sold at an average price of $92.45, for a total transaction of $231,125.00.
- On Tuesday, July 18th, Matt Scribner sold 2,500 shares of Inogen stock. The stock was sold at an average price of $94.21, for a total transaction of $235,525.00.
- On Friday, June 16th, Matt Scribner sold 2,500 shares of Inogen stock. The stock was sold at an average price of $91.54, for a total transaction of $228,850.00.
Inogen, Inc (NASDAQ:INGN) traded up 0.12% on Tuesday, reaching $104.49. 110,909 shares of the company were exchanged. The stock has a market capitalization of $2.17 billion, a P/E ratio of 90.70 and a beta of 1.02. Inogen, Inc has a 12-month low of $50.24 and a 12-month high of $104.88. The company’s 50-day moving average price is $95.08 and its 200-day moving average price is $86.66.
Inogen (NASDAQ:INGN) last released its earnings results on Thursday, August 3rd. The medical technology company reported $0.38 earnings per share (EPS) for the quarter, beating the Zacks’ consensus estimate of $0.28 by $0.10. Inogen had a net margin of 10.36% and a return on equity of 12.45%. The company had revenue of $64.10 million for the quarter, compared to the consensus estimate of $59.99 million. During the same quarter in the previous year, the company earned $0.25 EPS. Inogen’s quarterly revenue was up 17.4% compared to the same quarter last year. Equities research analysts anticipate that Inogen, Inc will post $1.21 earnings per share for the current fiscal year.
TRADEMARK VIOLATION WARNING: “Matt Scribner Sells 2,500 Shares of Inogen, Inc (INGN) Stock” was reported by Stock Observer and is the property of of Stock Observer. If you are accessing this story on another domain, it was illegally stolen and republished in violation of U.S. and international trademark and copyright laws. The legal version of this story can be read at https://www.thestockobserver.com/2017/09/12/matt-scribner-sells-2500-shares-of-inogen-inc-ingn-stock.html.
Institutional investors and hedge funds have recently added to or reduced their stakes in the business. Ameritas Investment Partners Inc. acquired a new position in Inogen during the first quarter worth $109,000. Schroder Investment Management Group acquired a new position in Inogen during the second quarter worth $132,000. Victory Capital Management Inc. raised its holdings in Inogen by 36.1% during the first quarter. Victory Capital Management Inc. now owns 1,729 shares of the medical technology company’s stock worth $134,000 after buying an additional 459 shares during the last quarter. State of Alaska Department of Revenue raised its holdings in Inogen by 4.1% during the first quarter. State of Alaska Department of Revenue now owns 1,790 shares of the medical technology company’s stock worth $138,000 after buying an additional 70 shares during the last quarter. Finally, Sei Investments Co. raised its holdings in Inogen by 38.1% during the second quarter. Sei Investments Co. now owns 1,606 shares of the medical technology company’s stock worth $153,000 after buying an additional 443 shares during the last quarter.
INGN has been the topic of a number of research analyst reports. Zacks Investment Research lowered shares of Inogen from a “strong-buy” rating to a “hold” rating in a report on Tuesday, July 11th. J P Morgan Chase & Co raised their price objective on shares of Inogen to $102.00 and gave the stock an “overweight” rating in a report on Monday, June 26th. BidaskClub upgraded shares of Inogen from a “buy” rating to a “strong-buy” rating in a report on Tuesday, August 8th. Piper Jaffray Companies restated a “hold” rating and set a $90.00 price objective on shares of Inogen in a report on Tuesday. Finally, Needham & Company LLC raised their price objective on shares of Inogen from $96.00 to $108.00 and gave the stock a “strong-buy” rating in a report on Friday, June 9th. Four research analysts have rated the stock with a hold rating, two have issued a buy rating and one has given a strong buy rating to the company. Inogen currently has an average rating of “Buy” and a consensus target price of $91.33.
Inogen Company Profile
Inogen, Inc is a medical technology company. The Company develops, manufactures and markets portable oxygen concentrators used to deliver supplemental long-term oxygen therapy to patients suffering from chronic respiratory conditions. The Company’s Inogen One systems concentrate the air around the patient to offer a single source of supplemental oxygen anytime, anywhere with a portable device.
Receive News & Ratings for Inogen Inc Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Inogen Inc and related companies with MarketBeat.com's FREE daily email newsletter.